Equities Analysts Set Expectations for CAPR Q2 Earnings

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Equities researchers at B. Riley issued their Q2 2025 earnings estimates for shares of Capricor Therapeutics in a report issued on Wednesday, June 25th. B. Riley analyst M. El-Saadi forecasts that the biotechnology company will earn ($0.48) per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share. B. Riley also issued estimates for Capricor Therapeutics’ Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at $1.37 EPS, FY2027 earnings at ($0.27) EPS, FY2028 earnings at $1.47 EPS and FY2029 earnings at $2.59 EPS.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same quarter last year, the company earned ($0.31) earnings per share.

CAPR has been the topic of a number of other reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Roth Capital reiterated a “buy” rating and set a $31.00 target price on shares of Capricor Therapeutics in a report on Tuesday, June 17th. HC Wainwright reiterated a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a report on Tuesday, June 24th. Wall Street Zen lowered shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Finally, Oppenheimer reduced their target price on shares of Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating on the stock in a report on Monday, June 23rd. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $33.75.

Capricor Therapeutics Stock Up 9.5%

Capricor Therapeutics stock opened at $11.15 on Monday. The firm has a market cap of $509.33 million, a PE ratio of -7.85 and a beta of 0.85. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40. The company’s 50 day moving average is $10.88 and its two-hundred day moving average is $12.33.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its holdings in shares of Capricor Therapeutics by 39.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock valued at $3,902,000 after purchasing an additional 116,373 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Capricor Therapeutics by 8.1% in the 1st quarter. Rhumbline Advisers now owns 49,814 shares of the biotechnology company’s stock valued at $473,000 after purchasing an additional 3,731 shares in the last quarter. Woodline Partners LP raised its holdings in shares of Capricor Therapeutics by 15.8% in the 1st quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock valued at $6,921,000 after purchasing an additional 99,384 shares in the last quarter. Octagon Capital Advisors LP acquired a new stake in Capricor Therapeutics during the 1st quarter worth $4,270,000. Finally, AWM Investment Company Inc. acquired a new stake in Capricor Therapeutics during the 1st quarter worth $833,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.